Table 3.
FDA-approved ADCs for cancer therapy.
| Product | ADC | Approval date | Target | FDA-approved indication |
|---|---|---|---|---|
| Adcertris | Brentuximab vedotin | 2011 | CD-30 | Hodgkin's lymphoma |
| Kadcyla | Trastuzumab emtansine | 2013 | HER-2 | HER2-positive advanced breast cancer |
| Besponsa | Inotuzumab ozogamicin | 2017 | CD22 | Relapsed or refractory CD22-positive acute lymphoblastic leukemia |
| Mylotarg | Gemtuzumab ozogamicin | 2017 | CD33 | CD33-positive newly diagnosed acute myeloid leukemia |
| Lumoxiti | Moxetumomab pasudotox-tdfk | 2018 | CD22 | Adult patients with relapsed or refractory hairy cell leukemia |
| Policy | Polatuzumab vedotin-piiq | 2019 | CD-79 b | Adult patients with relapsed or refractory diffuse large B-cell lymphoma |
| Padcev | Enfortumab vedotin-ejfv | 2019 | Nectin-4 | Patients with locally advanced or metastatic urothelial cancer |
| Enhertu | Fam-trastuzumab Deruxtecan-nxki | 2019 | HER-2 | Adult patients with HER2-positive unresectable or metastatic breast cancer |